'%3e%3cg id='Final-Copy-2_2_' transform='translate(1275.000000, 200.000000)'%3e%3cpath class='st0' d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg id='final---dec.11-2020'%3e%3cg id='_x30_208-our-toggle' transform='translate(-1275.000000, -200.000000)'%3e%3cg id='Final-Copy-2' transform='translate(1275.000000, 200.000000)'%3e%3cpath class='st1' d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z M1.6,7c0-3.2,2.6-5.8,5.8-5.8 h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath id='x' class='st2' d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0 l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8 c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath id='y' class='st3' d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0 L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Bulletin 24-5
Early Notification of Changes to Donor Eligibility Requirements (Appendix II) and DRAIs
Read more
Bulletin 24-4
FDA Determines Zika Virus No Longer an RCDAD, Screening Can Be Suspended and Remain in Regulatory and Standards Compliance
Read more
Bulletin 24-3
Standards Committee Determines That the Use of Dis-Spray Does Not Qualify as an Embalming Procedure
Read more
Bulletin 23-7
AATB Physicians Council Recommends Discontinued Use of SARS-CoV-2/COVID-19 and Mpox Virus (MPXV) Addendums
Read more
Bulletin 23-4
Standards Enforcement Discretion for Cardiac and Vascular Tissue: Total Ischemic Time, D5.400 and E2.520
Read more
Bulletin 23-3
Update to Availability of Bio-Rad’s Genetic Systems™ HIV-1/HIV-2 PLUS O EIA Assay
Read more
Bulletin 23-2
Potential Shortage of HIV-1/HIV-2 Plus O EIA Test Kits and Impact on Donor Screening and/or Testing
Read more
Bulletin 22-2
Recommendation Issued to Tissue Banks Regarding the Risk of Mtb Transmission
Read more
Bulletin 21-8
Announcement of Changes to Standards Entering a Six-Month Preparatory Period on July 31, 2021
Read more
Bulletin 21-7
Changes to Standards: Revised AATB Standards Coming into Effect July 31, 2021
Read more
Bulletin 21-6
Potential Mycobacterium tuberculosis Transmission Through Tissue Transplantation
Read more
Bulletin 21-5
Update on Considerations for Tissue Donor Risk Assessment of COVID-19/SARS-CoV-2 Infection
Read more
Bulletin 21-3
Announcement of Changes to Standards Entering a Six-Month Implementation Period on January 31, 2021
Read more
Bulletin 20-11
Recommendations on Personal Protective Equipment (PPE) for Tissue Bank Recovery and Processing Personnel
Read more
Bulletin 20-6
AATB Issues Advanced Copies of the Revised Standards That Come Into Effect on July 31, 2020
Read more
Bulletin 20-5
AATB Provides Additional Details on the Standard Revision Announcement System Adopted on July 31, 2019
Read more
Bulletin 19-2
FDA Announced Changes to CDC's ZIKV Blood and Tissue Safety Webpage and World Map
Read more
IMPORTANT NOTICE: AATB Standards are subject to revision at any time pursuant to the Association’s procedures. Notice of each such revision is given by AATB via a “Bulletin” that announces those changes and their respective effective dates. Persons seeking to determine the current provisions of Standards should always review the Bulletins for any such announcement of revisions to Standards or may request a current and effective copy of the Standards by sending a request to the AATB mailbox: accreditation@aatb.org.